EXHIBIT 10.8
* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
AMENDMENT NINE TO
DEVELOPMENT AGREEMENT
This Amendment Nine, made as of April 15, 2002 ("Effective Date")
between SRI International, a California, non-profit and public benefit
corporation, having, a place of business located at 000 Xxxxxxxxxx Xxxxxx, Xxxxx
Xxxx, XX 00000 (hereinafter "SRI") and Lipid Sciences Incorporated, an Arizona
corporation, having a place of business located at 0000 Xxxx Xxxxxx Xxxxxxx,
Xxxxx 000, Xxxxxxxxxx, XX 00000 (hereinafter "LSI").
WHEREAS, SRI and LSI have entered into a development agreement having
an effective date of October 6, 2000 and an Amendment One thereto dated March 8,
2001 and Amendment Two dated March 28, 2001; Amendment Three dated May 12, 2001;
Amendment Four dated May 13, 2001, Amendment Five dated May 13, 2001, Amendment
Six dated December 5, 2001, Amendment Seven dated October 6, 2000, and Amendment
Eight dated February 13, 2002, (hereinafter individually and collectively
"Development Agreement") and which the parties hereby amend; and
WHEREAS, the parties intend that this Amendment Nine provide for the
details of additional work related to Phase 2 of the test and selection of the
sensor development for quantification of N-butanol and Di-isopropyl ether
concentration. Both parties recognize that this work is outside of the scope of
the Phase 11 Development Plan of the Development Agreement and therefore
increases the authorized value of the contract by $343,036 (which is the cost of
the effort less $35,000 that LSI will set aside for purchasing materials
directly).
NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, SRI and LSI agree as follows:
1. For consistency and unless otherwise defined herein all
initially capitalized terms shall have the meaning set forth
in the Development Agreement.
2. The scope of work and project cost, which the parties agree
are outside of the scope of Phase 11 Development Plan of the
Development Agreement are attached hereto as Exhibit A (SRI
Proposal PYC 02-082)
3. Unless expressly amended by this Amendment Nine, all other
terms and conditions of the Development Agreement shall remain
in full force and effect.
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date last subscribed below.
SRI International Lipid Sciences, Incorporated
By: /s/ V. Xxxx Xxxxxxxx By: /s/ Xxxx Xxxxxxx
--------------------------- -----------------
V. Xxxx Xxxxxxxx Xxxx Xxxxxxx, Ph.D.
Group Manager, Contracts President and Chief Executive Officer
EXHIBIT A
[ * ]
